The authors wrote, “Despite advancements in molecular subtyping and prognostic assessment, uncertainties persist regarding the optimal management of DLBCL, highlighting the need for localized investigations to better understand treatment responses and outcomes within specific patient populations.”
The study was conducted between August 8, 2022, and April 8, 2023. It included patients who were newly diagnosed with DLBCL aged between 20 and 70 years with an average age of 46.4 ± 9.3 years and excluded those who had received prior treatment. The study population comprised 55 (57.9%) males and 40 (42.1%) females. Employing a predefined data collection form, data on demographic characteristics, duration of disease, and CR outcomes were gathered.
The results revealed that following six cycles of R-CHOP therapy, the majority of patients (80 patients), representing 84.2% of the patient population, achieved CR. With regard to age distribution, 43 (45.3%) patients were aged ≤45 years, while the remaining were in the >45 years age group. The duration of the disease was documented as ≤3 months in 60 (63.2%) cases; however, it surpassed 3 months in 35 (36.8%) cases. The results revealed that assessment based on BMI categories demonstrated CR in 66.7% of cases in individuals with a BMI level of <18.5 kg/m2; 40 (81.6%) cases in those with a BMI between 18.5 kg/m2 and 24.9 kg/m2; and 19 (51.3%) cases in individuals with a BMI between 25 kg/m2 and 30 kg/m2.
Based on their findings, the authors concluded that their study accentuates the effectiveness of R-CHOP therapy in attaining CR among patients with DLBCL patients, with a considerable percentage experiencing favorable outcomes.
The authors wrote, “While R-CHOP therapy demonstrates promising efficacy in achieving CR, concerns regarding late adverse effects persist. Addressing these challenges requires continued research efforts to validate novel prognostic markers and develop alternative treatment approaches, ultimately improving patient outcomes and reducing the global burden of DLBCL.”
The content contained in this article is for informational purposes only. The content is not intended to be a substitute for professional advice. Reliance on any information provided in this article is solely at your own risk.
